[ACST] Acasti Pharma, Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 14.14 M
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For ACST
ACST is in the long-term down -98% below S&P in 12 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Acasti Pharma Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of therapies for abnormalities in blood lipids, and the treatment and prevention of various cardiometabolic disorders in Canada and the United States. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trials for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.
See how to gain 20% in 14 sec with TrendsInvesting
Fundamental Ratios
| Shares Outstanding | 10.71 M | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | |||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | Sales Growth - Q/Q | P/E | ||||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | ROE | ROI | ||||
| Current Ratio | Quick Ratio | Long Term Debt/Equity | Debt Ratio | ||||
| Gross Margin | Operating Margin | Net Profit Margin | Dividend Payout Ratio | ||||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | Cash From Investing Activities | Cash From Operating Activities | Gross Profit | ||||
| Net Profit | Operating Profit | Total Assets | Total Current Assets | ||||
| Total Current Liabilities | Total Debt | Total Liabilities | Total Revenue |
Technical Data
| High 52 week | 3.1 | Low 52 week | 0.63 | Last close | 0.71 | Last change | 1.59% |
| RSI | 36.35 | Average true range | 0.04 | Beta | 0.3 | Volume | 4.94 M |
| Simple moving average 20 days | -2.49% | Simple moving average 50 days | -23.16% | Simple moving average 200 days | -39.8% |
Performance Data
| Performance Week | 7.92% | Performance Month | -34.26% | Performance Quart | -31.73% | Performance Half | -44.96% |
| Performance Year | -43.2% | Performance Year-to-date | -24.69% | Volatility daily | 6.55% | Volatility weekly | 14.65% |
| Volatility monthly | 30.03% | Volatility yearly | 104.04% | Relative Volume | 5202.7% | Average Volume | 196.58 K |
| New High | New Low |
News
2021-03-08 17:30:00 | Acasti Pharma Provides Update on Recent Financing Activities
2021-02-09 06:55:00 | Acasti Pharma Announces Results for Third Quarter of Fiscal 2021
2021-01-27 06:55:00 | Acasti Pharma Provides Update on Recent Financing Activities
2020-12-25 12:00:05 | Acasti ACST Moves to Buy: Rationale Behind the Upgrade
2020-12-23 15:24:00 | Acasti Pharma Unaware of Any Material Change
2020-11-16 06:55:00 | Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2021
2020-11-12 05:43:52 | Here's Why Acasti Pharma CVE:ACST Must Use Its Cash Wisely
2020-09-29 06:55:00 | Acasti Announces Review Process of Strategic Alternatives
2020-09-16 06:55:00 | Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer
2020-09-11 07:00:00 | Acasti Announces Filing and Mailing of Information Circular and Change in Record Date
2020-09-01 14:10:28 | Acasti Pharma Stock Loses a Wall Street Supporter
2020-08-31 07:00:00 | Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia
2020-08-14 12:00:04 | What Makes Acasti ACST a New Buy Stock
2020-08-13 08:30:00 | Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021
2020-07-31 07:55:00 | Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020
2020-07-06 14:37:43 | Why Acasti Pharma's Stock Is Trading Higher Today
2020-06-29 09:45:12 | Acasti Pharma Provides Fiscal 2020 Year-End Business Update
2020-06-19 08:00:10 | Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package
2020-06-04 21:49:01 | Hedge Funds Souring On Acasti Pharma Inc. ACST
2020-05-06 06:25:05 | Does The Acasti Pharma Inc. CVE:ACST Share Price Fall With The Market?
2020-04-30 08:30:10 | Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA
2020-04-20 08:30:10 | Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada
2020-04-01 08:30:10 | Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June
2020-03-11 08:00:10 | Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico
2020-03-06 06:50:52 | Amarin Stock Looks Like a Heart-Healthy Buy on the Dip
2020-02-28 17:00:10 | Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements
2020-02-28 14:48:40 | Look Anywhere but Acasti Pharma Stock for Opportunity
2020-02-28 10:07:03 | Confounding Decline Creates an Opportunity in Amarin Stock
2020-02-14 11:41:45 | Risks Remain, but Amarin Stock Is a Buy at Today’s Prices
2020-02-14 08:00:10 | Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020
2020-02-13 09:00:10 | Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call
2020-02-11 11:27:42 | 3 Beaten-Down Biotech Stocks With +50% Upside Potential
2020-02-11 07:23:06 | The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology
2020-02-10 07:00:10 | Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre
2020-01-17 11:07:12 | Does Acasti Stock Have a Future?
2020-01-17 06:30:07 | Why Amarin Stock Is Poised for a Healthy 2020
2020-01-14 09:46:02 | AstraZeneca to End Phase III Study on Fish Oil Heart Drug
2020-01-14 07:55:40 | The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug
2020-01-13 16:22:46 | This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled
2020-01-13 14:31:00 | Amarin's stock surges, as rival drugs from AstraZeneca, Acasti disappoint
2020-01-13 13:38:00 | Neptune Provides Updates on Non-Core Investments
2020-01-13 11:07:00 | Amarin Stock Is Surging as Rival Makers of Fish-Oil Heart Drugs Fall Short
2020-01-13 09:40:46 | This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled
2020-01-13 06:00:10 | Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre
2020-01-10 10:59:53 | All Bets Are Off for Amarin Stock
2020-01-09 08:56:44 | 3 Healthcare Stocks With Big Catalysts in January
2019-12-24 09:51:09 | Acasti Delays Data Readout For Drug To Treat Elevated Triglycerides
2019-12-24 08:13:19 | Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 24, 2019: TSLA, WCC, ACST, YMAB, ITCI
2019-12-24 07:24:51 | The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict